{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T03:34:27Z","timestamp":1790652867184,"version":"4.1.0"},"reference-count":7,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T00:00:00Z","timestamp":1752451200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T00:00:00Z","timestamp":1752451200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J GEN INTERN MED"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s11606-025-09717-x","type":"journal-article","created":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T18:00:51Z","timestamp":1752516051000},"page":"245-248","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Revenue, Patents, and New Generic Competition for Prescription Drugs in the USA"],"prefix":"10.1007","volume":"41","author":[{"given":"S. Sean","family":"Tu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron S.","family":"Kesselheim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph S.","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5902-6414","authenticated-orcid":false,"given":"Ravi","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,14]]},"reference":[{"key":"9717_CR1","unstructured":"Conrad R, Lutter R. Generic competition and drug prices: new evidence linking greater generic competition and lower generic drug prices. 2019; https:\/\/www.fda.gov\/media\/133509\/download. Accessed December 24, 2024."},{"issue":"2","key":"9717_CR2","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1002\/cpt.1314","volume":"105","author":"R Gupta","year":"2019","unstructured":"Gupta R, Shah ND, Ross JS. Generic Drugs in the United States: Policies to Address Pricing and Competition. Clin Pharmacol Ther. 2019;105(2):329-337.","journal-title":"Clin Pharmacol Ther."},{"issue":"12","key":"9717_CR3","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1016\/j.jval.2018.04.1827","volume":"21","author":"RF Beall","year":"2018","unstructured":"Beall RF, Darrow JJ, Kesselheim AS. A Method for Approximating Future Entry of Generic Drugs. Value Health. 2018;21(12):1382-1389.","journal-title":"Value Health."},{"key":"9717_CR4","unstructured":"SSR Health. Prescription Brand Net Pricing Data and Analysis. https:\/\/www.ssrhealth.com\/. Accessed May 27, 2024."},{"issue":"5","key":"9717_CR5","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1001\/jama.2023.11525","volume":"330","author":"SS Tu","year":"2023","unstructured":"Tu SS, Kesselheim AS, Wetherbee K, Feldman WB. Changes in the Number of Continuation Patents on Drugs Approved by the FDA. JAMA. 2023;330(5):469-470.","journal-title":"JAMA."},{"key":"9717_CR6","unstructured":"IQVIA Institute for Human Data Science. Medicine Use and Spending in the U.S. May 2019."},{"key":"9717_CR7","first-page":"1673","volume":"99","author":"SS Tu","year":"2022","unstructured":"Tu SS, Lemley MA. What Litigators Can Teach the Patent Office About Pharmaceutical Patents. Washington University Law Review. 2022;99:1673.","journal-title":"Washington University Law Review."}],"container-title":["Journal of General Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-025-09717-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11606-025-09717-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-025-09717-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:03:13Z","timestamp":1783987393000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11606-025-09717-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,14]]},"references-count":7,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["9717"],"URL":"https:\/\/doi.org\/10.1007\/s11606-025-09717-x","relation":{},"ISSN":["0884-8734","1525-1497"],"issn-type":[{"value":"0884-8734","type":"print"},{"value":"1525-1497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,14]]},"assertion":[{"value":"26 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr Tu reports consulting for purchasers of lenalidomide- and abiraterione acetate-containing products outside the submitted work. Dr. Kesselheim served as a consultant for Alosa, and serves as an expert witness for a class of state attorneys general and payors in a case against a large group of generic drug manufacturers related to allegations of price fixing, for payers in a case against J&J related to introduction of biosimilar Stelara, and for a class of individual plaintiffs in a case against Gilead relating to its tenofovir-containing products. Dr. Ross currently receives research support through Yale University from Johnson and Johnson to develop methods of clinical trial data sharing, from the Food and Drug Administration for the Yale-Mayo Clinic Center for Excellence in Regulatory Science and Innovation (CERSI) program (U01FD005938), from the Agency for Healthcare Research and Quality (R01HS022882), and from Arnold Ventures; formerly received research support from the Medical Device Innovation Consortium as part of the National Evaluation System for Health Technology (NEST) and from the National Heart, Lung and Blood Institute of the National Institutes of Health (NIH) (R01HS025164, R01HL144644); and in addition, Dr. Ross was an expert witness at the request of Relator\u2019s attorneys, the Greene Law Firm, in a qui tam suit alleging violations of the False Claims Act and Anti-Kickback Statute against Biogen Inc. that was settled September 2022. In the past 3\u00a0years, Dr. Gupta reports receiving personal fees from Alosa Health and Sunday Health for unrelated work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Drs. Tu and Gupta had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Access and Responsibility"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}